```html

Warfarin‑Induced Skin Necrosis

What is Warfarin‑induced skin necrosis?

Warfarin‑induced skin necrosis (WISN) is a rare, potentially life‑threatening complication that can occur shortly after a patient begins therapy with warfarin, a vitamin‑K antagonist used to prevent blood clots. The condition presents as painful, red or purplish plaques that rapidly progress to black, necrotic (dead) skin. The necrosis most often involves fatty areas such as the breasts, thighs, buttocks, and abdomen, but any skin surface can be affected.

WISN results from a paradoxical hyper‑coagulable state caused by an early, disproportionate drop in protein C and protein S (natural anticoagulant proteins) while the pro‑coagulant clotting factors (especially factors II, VII, IX, and X) remain functional. The resultant microvascular thrombosis deprives skin tissue of oxygen, leading to cell death.

Although it occurs in less than 0.01 % of patients on warfarin, the rapid evolution of skin lesions and the risk of systemic thrombosis make early recognition essential.

Common Causes

WISN does not arise from a single factor; it usually reflects an interplay of patient‑specific risk factors and medication‑related issues. The most frequently reported contributors include:

• High initial warfarin dose – loading doses >5 mg/day increase the risk of a rapid protein C decline.
• Protein C or protein S deficiency – inherited or acquired deficiencies amplify the hyper‑coagulable window.
• Female sex – women are 2–3 times more likely to develop WISN, possibly due to higher sub‑cutaneous fat distribution.
• Obesity – excess adipose tissue provides a larger substrate for micro‑vascular thrombosis.
• Recent surgery or trauma – tissue injury predisposes to clot formation.
• Concurrent use of other pro‑thrombotic drugs – e.g., estrogen‑containing contraceptives, activated protein C inhibitors.
• Liver disease – impairs synthesis of clotting factors and natural anticoagulants.
• Rapid switch from heparin to warfarin – especially without adequate overlap.
• Genetic variants affecting warfarin metabolism (e.g., CYP2C9*2/*3) that lead to unpredictable INR spikes.
• Underlying autoimmune disorders such as antiphospholipid syndrome, which already favour thrombosis.

Associated Symptoms

Skin necrosis rarely occurs in isolation. Patients often notice additional signs that point to a systemic hyper‑coagulable state:

• Painful, tender plaques that become firm and indurated within hours.
• Red‑purple discoloration that evolves into a well‑demarcated, dusky or black eschar.
• Swelling (edema) around the lesion, sometimes extending beyond the visible border.
• Warmth and a “strawberry” appearance of the overlying skin in early stages.
• Fever, chills, or malaise—suggesting secondary infection.
• Unexplained bruising (purpura) elsewhere on the body.
• Hypotension or tachycardia if extensive thrombosis leads to a systemic response.
• Elevated INR (>3) despite appropriate dosing, indicating over‑anticoagulation.
• Signs of deep‑vein thrombosis (leg swelling, pain) or pulmonary embolism (shortness of breath, chest pain).

When to See a Doctor

Because WISN can progress to full‑thickness skin loss and systemic clotting within days, timely medical attention is critical. Seek care immediately if you notice:

• Sudden, painful redness on the breasts, thighs, buttocks, or abdomen within the first 3–10 days of starting warfarin.
• Rapid spread of the discoloration or development of blackened, dead‑appearing skin.
• Fever, increasing pain, or drainage from the lesion (possible infection).
• New swelling in the legs, shortness of breath, or chest pain.
• Any skin changes that do not improve after 24 hours of holding warfarin.

Even if the lesion seems minor, call your prescribing clinician or present to the emergency department because early reversal of warfarin and alternative anticoagulation can save tissue and life.

Diagnosis

Diagnosing WISN involves a combination of clinical suspicion, laboratory data, and sometimes imaging. The typical work‑up includes:

1. Detailed History & Physical Examination

• Time line of warfarin initiation, dose, and any loading regimen.
• Previous episodes of thrombosis or known protein C/S deficiency.
• Physical description of the skin lesions—size, color, border, tenderness.

2. Laboratory Tests

• International Normalized Ratio (INR) – often >3 at presentation.
• Complete blood count (CBC) – to assess for leukocytosis (infection) or anemia.
• Coagulation profile – PT, aPTT, and levels of protein C, protein S, antithrombin.
• D‑dimer – may be elevated, indicating ongoing thrombosis.
• Baseline liver function tests – to evaluate warfarin metabolism.

3. Skin Biopsy (if diagnosis uncertain)

A punch biopsy taken from the edge of the lesion typically shows:

• Dermal blood vessel thrombosis without vasculitis.
• Ischemic necrosis of the epidermis and subcutaneous fat.

Histology helps exclude other causes such as cellulitis, purpura fulminans, or necrotizing fasciitis.

4. Imaging (selected cases)

• Duplex ultrasonography of the affected limb to rule out deep‑vein thrombosis.
• CT or MRI if there is concern for deep tissue involvement.

Treatment Options

Management aims to stop the progression of skin necrosis, reverse the pro‑thrombotic effect of warfarin, and provide alternative anticoagulation when needed.

1. Immediate Measures

• Discontinue warfarin at the first sign of necrosis.
• Vitamin K administration – 2.5–5 mg IV or subcutaneously to restore functional clotting factor synthesis (usually given as a slow IV push).
• Fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) – rapid reversal of over‑anticoagulation, especially if INR >4 or bleeding is present.

2. Alternative Anticoagulation

• Low‑molecular‑weight heparin (LMWH) (e.g., enoxaparin 1 mg/kg SC q12 h) – preferred while warfarin is held.
• Unfractionated heparin infusion with aPTT monitoring – useful in patients with renal impairment.
• Once the protein C level normalizes (usually 5–7 days), warfarin may be re‑introduced at a very low dose (≤2 mg) with strict INR monitoring and continued heparin overlap.

3. Supportive Skin Care

• Clean, non‑adhesive dressings to prevent secondary infection.
• Topical antimicrobial agents (e.g., mupirocin) if there is colonization.
• Analgesics – acetaminophen or short courses of opioids for severe pain.
• Consultation with a wound‑care specialist or dermatologist for debridement if necrosis is extensive.

4. Surgical Intervention

• Early excision and grafting may be required for large or full‑thickness lesions.
• In cases of compartment syndrome or rapidly expanding necrosis, urgent fasciotomy is indicated.

5. Treat Underlying Deficiencies

• If protein C or protein S deficiency is confirmed, consider replacement therapy:
  • Protein C concentrate (e.g., Ceprotin) 100 U/kg IV every 6 h until clinical stability.
  • Plasma exchange in severe, refractory cases.

Prevention Tips

Because WISN is most likely to develop during the first week of therapy, careful initiation and monitoring can markedly reduce risk:

• Start with a low dose (2–3 mg/day) in patients with known risk factors; avoid high loading doses.
• Use bridging anticoagulation (heparin or LMWH) for at least 4–5 days while protein C levels recover.
• Check INR daily (or every other day) until it stabilizes within the therapeutic range (2.0–3.0 for most indications).
• Screen for protein C, protein S, and antithrombin deficiencies before initiating warfarin in patients with a personal or family history of thrombosis.
• Educate patients about early skin changes and instruct them to report any painful, reddish patches immediately.
• Consider alternative anticoagulants (direct oral anticoagulants – DOACs) in patients at high risk for WISN, especially when long‑term warfarin therapy is not mandatory.
• Maintain good nutrition and vitamin K intake consistency to avoid wide swings in INR.
• Avoid concomitant estrogen therapy or high‑dose corticosteroids without discussing the added thrombotic risk.

Emergency Warning Signs

Key Take‑aways

• Warfarin‑induced skin necrosis is a rare but serious complication occurring within days of starting warfarin.
• Early recognition—painful red or purple plaques that turn black—is essential to prevent extensive tissue loss.
• Prompt discontinuation of warfarin, vitamin K reversal, and bridging with heparin are the cornerstones of treatment.
• Patients with protein C or protein S deficiency, high initial warfarin doses, obesity, or recent surgery are at higher risk.
• Prevention hinges on careful dosing, overlap anticoagulation, and patient education.

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, Blood journal, and the American College of Chest Physicians (ACCP) guidelines.

```